Twist Bioscience Corporation (NASDAQ:TWST) Receives $45.88 Average PT from Analysts

Twist Bioscience Corporation (NASDAQ:TWST) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $45.8750.

A number of equities research analysts recently weighed in on TWST shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Barclays increased their target price on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Evercore lifted their price target on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Finally, Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, February 3rd.

Insider Buying and Selling

In related news, CFO Adam Laponis sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the completion of the sale, the chief financial officer owned 130,031 shares of the company’s stock, valued at $6,501,550. This trade represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jan Johannessen sold 2,200 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $47.91, for a total transaction of $105,402.00. Following the completion of the transaction, the director owned 17,754 shares of the company’s stock, valued at $850,594.14. This trade represents a 11.03% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 40,392 shares of company stock valued at $1,840,796. Insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Stifel Financial Corp raised its position in shares of Twist Bioscience by 3.6% during the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after acquiring an additional 271 shares during the last quarter. D.A. Davidson & CO. boosted its holdings in Twist Bioscience by 1.2% in the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after acquiring an additional 305 shares during the last quarter. CWM LLC boosted its holdings in Twist Bioscience by 9.4% in the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after acquiring an additional 407 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares during the period. Finally, California State Teachers Retirement System raised its holdings in Twist Bioscience by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares during the last quarter.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $43.28 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The business’s fifty day moving average price is $44.94 and its two-hundred day moving average price is $35.17. Twist Bioscience has a fifty-two week low of $23.30 and a fifty-two week high of $57.88. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of -33.81 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The firm had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business’s revenue was up 16.9% compared to the same quarter last year. As a group, analysts predict that Twist Bioscience will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.